Ziprasidone/Geodon
Treatment Resistant Bipolar Disorder
Dr. Stavroula RakitziPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
66 Active assets in the Treatment Resistant Bipolar Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Asenapine Dr. Stavroula Rakitzi | Phase 4 | BBB |
CITALOPRAM University of Texas Southwestern Medical Center | Phase 4 | BBB |
LITHIUM, ELEMENTAL University of Aarhus | Phase 4 | BBB |
Paroxetine Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | Phase 4 | BBB |
Cipralex First Affiliated Hospital of Zhejiang University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Ziprasidone/Geodon is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →